Glycoproteomics-based Liquid-biopsy LDT Development Service for Pancreas Carcinoma
Services Published Data
Glycoprotein Biomarkers for the Diagnosis of Pancreas Carcinoma
Pancreas carcinoma is characterized by a poor prognosis, often diagnosed at an incurable stage due to the lack of early symptoms. One commonly used serum glycoprotein biomarker is the carbohydrate antigen (CA19-9), which is structurally a sialylated Lewis A antigen present on various proteins. However, CA19-9 has limitations, including its reliance on the Lewis-negative genotype. Consequently, there is an urgent need for a more reliable and universally applicable biomarker or panel for diagnosing pancreatic cancer. Glycan structures of glycoproteins undergo alternations in pancreas carcinoma, detectable in biological fluids of cancer patients. Recent advancements in glycoproteomic technology, particularly mass spectrometry, have enabled researchers to explore alternative serum glycoprotein biomarker candidates that can overcome the limitations of CA19-9. This innovative approach offers the potential to discover new markers that could enhance the accuracy and reliability of early pancreatic cancer diagnosis.
Glycoproteomics-based Liquid-biopsy LDT Development for Pancreas Carcinoma at Creative Biolabs
Creative Biolabs is proud to launch Glycoproteomics-based Liquid-biopsy LDT Development for pancreas carcinoma. Our LDT development facilitates the discovery of serum glycoprotein biomarkers from large-scale detection of liquid biopsy samples and we provide a comprehensive analysis of glycoproteomic data. Through our glycoproteomics-based liquid-biopsy LDT services, the identification of a promising serum glycoprotein biomarker or biomarker panel for pancreatic carcinoma becomes attainable.
Fig.1 LDT development for serum biomarker discovery.
Advantages of Our LDT Services
-
High-throughput analysis: dealing with a large number of samples
-
High-precision detection: utilizing effective fragmentation methods
-
Comprehensive services: combining with performance analysis of candidate biomarkers
-
Professional team of experts with extensive experience
Published data
Pancreatic ductal adenocarcinoma (PDAC) is the main type of pancreatic cancer, with an extremely low five-year survival rate of only 5%-8%, and most patients have already developed to the late stage when they are first diagnosed and cannot undergo surgical treatment. Traditional detection methods are not effective enough, and new blood biomarkers are urgently needed to improve diagnostic accuracy. This study conducted an in-depth analysis of the serum N-glycome of PDAC patients and found that their glycosylation characteristics were significantly different from those of normal people, especially in terms of enhanced branching and fucosylation. The constructed classification model showed high sensitivity and specificity in different groups, laying the foundation for the development of new blood detection methods.
Fig.2 N-glycosylation analysis process of PDAC case samples.1
At Creative Biolabs, our LDT services in tandem with advanced analytical techniques hold great promise for identifying a more effective biomarker to address the challenges associated with pancreatic carcinoma diagnosis. Please don't hesitate to contact us for more information.
Reference
-
Vreeker, Gerda CM, et al. "Serum N-glycome analysis reveals pancreatic cancer disease signatures." Cancer Medicine 9.22 (2020): 8519-8529. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
Related Services
